3 Companies That More Than Doubled Analyst EPS Estimates

 | Feb 07, 2024 02:18PM ET

  • Merck & Co. beat Q4 2023 analyst estimates for a loss of 11 cents by 14 cents.
  • Seagate Technology beat fiscal Q2 2024 analyst estimates for a loss of 6 cents by 18 cents, marking its first profitable quarter in a year and potential bottom to the prolonged bearish cycle.
  • Southwest Airlines (NYSE:LUV) almost tripled Q4 2023 analyst EPS estimates.

Earnings season is well underway, and the winner-and-loser separation continues to grow. Of the companies that beat consensus analyst estimates, even fewer go well beyond and exceed analyst expectations.

Are these one-off events, financial engineering, lowballed forecasts or a sign of an improving trend? Three companies have more than doubled their EPS estimates in the transportation, computer and technology and medical sectors.

h2 Merck & Co. Inc./h2

Merck & Company Inc (NYSE:MRK), a leading global pharmaceuticals company, develops and manufactures prescription drugs for a diverse range of therapeutic areas, including cardiovascular diseases, neurosciences, oncology, immunology, infectious disease, vaccines and women's and animal health.

Its blockbuster drugs include Keytruda, with Q4 2023 sales growing 22% year-over-year (YoY) to $6.6 billion. Oncology saw Lynparza sales rise 8% YoY to $315 million. Gardasil sales rose 27% YoY to $1.9 billion, with strong global demand in China. Animal health sales rose 4% to $1.3 billion YoY in Q4 2023.

h2 Triple flush/h2

Merck reported Q4 2023 EPS of three cents, beating analyst estimates for a loss of 11 cents by 14 cents. Revenues grew 5.8% to $14,63 billion versus $14.49 billion consensus analyst estimates. Check out the sector heatmap on MarketBeat.

h2 Raising 2024 guidance /h2

Merck raised its full-year 2024 guidance with EPS of $8.44 to $8.59 versus $8.40 consensus analyst estimates. Revenues are expected between $62.7 billion to $64.2 billion versus $63.47 billion analyst estimates.

For the next decade, Merck raised its outlook for oncology revenues to grow over $20 billion, up from $10 billion. Cardiometabolic revenues should grow over $15 billion, up from $10 billion. Immunology should grow into the multi-billion range.

Merck CEO Robert Davis commented, “2023 was another very strong year for Merck. I am extremely pleased by the progress we’ve made to develop and deliver transformative therapies and vaccines that will help save and improve lives around the world. We reached more than 500 million people with our medicines last year alone.”

Look for Merck & Co. analyst ratings and price targets at MarketBeat. Find Merck & Co. peers and competitor stocks with the MarketBeat stock screener.